recent
outbreak
middl
east
respiratori
syndrom
mer
coronaviru
merscov
infect
led
laboratoryconfirm
mer
case
high
case
fatal
rate
pose
seriou
threat
global
public
health
call
develop
effect
safe
therapeut
prophylact
strategi
treat
prevent
merscov
infect
discuss
recent
studi
structur
merscov
spike
protein
role
viru
bind
entri
develop
merscov
entryfus
inhibitor
target
subunit
particularli
receptorbind
domain
rbd
subunit
especi
region
merscov
spike
protein
look
ahead
futur
applic
viral
entryfus
inhibitor
either
alon
combin
specif
nonspecif
merscov
replic
inhibitor
treatment
prevent
merscov
infect
june
saudi
man
suffer
sarslik
diseas
character
fever
cough
short
breath
admit
hospit
jeddah
eleven
day
later
die
respiratori
kidney
failur
dr
ali
moh
zaki
saudi
arabia
virologist
isol
new
coronaviru
ncov
patient
specimen
later
verifi
betacoronaviru
name
hcovemc
may
viru
renam
middl
east
respiratori
syndrom
coronaviru
merscov
intern
committe
taxonomi
virus
ictv
de
groot
et
al
juli
inform
confirm
case
middl
east
respiratori
syndrom
mer
includ
death
higher
case
fatal
rate
sar
lu
et
al
case
number
saudi
arabia
spike
april
enzym
protein
protein
e
protein
protein
n
protein
van
boheemen
et
al
merscov
sixth
human
coronaviru
known
infect
human
phylogenet
analysi
demonstr
merscov
close
relat
bat
coronavirus
sarscov
van
boheemen
et
al
lau
et
al
woo
et
al
suggest
merscov
origin
bat
may
serv
natur
reservoir
annan
et
al
anthoni
et
al
inde
coronavirus
isol
bat
south
africa
found
genet
relat
merscov
coronaviru
identifi
bat
saudi
arabia
nucleotid
ident
viru
human
index
casepati
milnepric
et
al
therefor
possibl
direct
transmiss
merscov
merscovlik
viru
bat
human
exclud
dromedari
camel
middl
east
africa
thought
intermedi
host
transmiss
merscov
bat
human
merscovspecif
antibodi
rna
fragment
widespread
camel
saudi
arabia
egypt
tunisia
nigeria
kenya
matsuyama
et
al
hemida
et
al
lau
et
al
reusken
et
al
reusken
et
al
barlan
et
al
human
infect
merscov
infect
camel
believ
occur
consumpt
anim
meat
milk
howev
recent
studi
suggest
merscov
may
also
airborn
sinc
genet
fragment
merscov
detect
air
sampl
barn
hous
infect
camel
azhar
et
al
although
investig
requir
confirm
claim
result
suggest
peopl
work
camel
take
everi
precaut
stop
spread
merscov
exampl
face
mask
worn
person
handl
camel
particularli
appear
sick
cellular
receptor
merscov
identifi
dipeptidyl
also
name
raj
et
al
typeii
transmembran
glycoprotein
wide
express
noncili
bronchial
epithelium
epitheli
cell
kidney
small
intestin
liver
parotid
gland
even
testi
prostat
lu
et
al
wide
distribut
good
accord
divers
clinic
manifest
recent
studi
demonstr
bat
coronaviru
could
also
use
entri
target
cell
howev
prefer
use
bat
human
merscov
prefer
util
human
receptor
absenc
exogen
proteas
merscov
pseudovirus
enter
bat
cell
merscov
pseudoviru
pseudoviru
abl
enter
human
human
cell
suggest
find
merscov
unlik
adapt
human
human
cellular
proteas
gain
entri
host
cell
like
coronavirus
merscov
enter
target
cell
two
pathway
either
endocytosi
plasma
membran
fusion
cathepsin
land
low
phdepend
independ
manner
respect
qian
et
al
shirato
et
al
phdepend
endocytosi
viru
entri
occur
intern
fusion
take
place
acid
environ
endosom
compart
belouzard
et
al
phindepend
plasma
membran
fusion
viru
abl
fuse
directli
cell
surfac
bind
receptor
effici
phdepend
endocytosi
matsuyama
et
al
belouzard
et
al
merscov
protein
cleav
serin
proteas
viru
matur
merscov
enter
cell
via
fusion
viral
envelop
plasma
membran
neutral
ph
caus
massiv
syncytia
format
qian
et
al
gierer
et
al
merscov
seem
enter
cell
mainli
plasma
membran
fusion
pathway
sinc
sever
merscovinfect
cell
line
lower
airway
liver
cell
form
syncytia
chan
et
al
lu
et
al
merscov
pseudoviru
treat
serin
proteas
becom
fusionactiv
suggest
plasma
membran
fusion
mediat
cleav
subunit
qian
et
al
gierer
et
al
emerg
merscov
caus
sever
respiratori
diseas
highlight
urgent
need
develop
effect
therapeut
prophylact
agent
treatment
prevent
merscov
infect
current
specif
antimerscov
drug
avail
vitro
studi
shown
nonspecif
antivir
drug
ribavirin
nucleosid
analog
could
inhibit
merscov
replic
chan
et
al
mycophenol
acid
mpa
commonli
use
clinic
immunosuppress
drug
prevent
reject
organ
transplant
report
effect
number
virus
includ
hepat
e
viru
hev
hcv
ye
et
al
influenza
viru
chan
et
al
west
nile
viru
morrey
et
al
chikungunya
viru
khan
et
al
yellow
fever
viru
leyssen
et
al
merscov
cell
cultur
chan
et
al
hart
et
al
poli
c
immunostimulatori
doublestrand
rna
analog
induc
antivir
respons
vitro
vivo
leyssen
et
al
kumar
et
al
perlman
colleagu
shown
treatment
mice
express
human
poli
c
merscov
challeng
significantli
acceler
viru
clearanc
type
interferon
ifn
includ
report
effect
inhibit
merscov
replic
vitro
cell
cultur
chan
et
al
recent
number
compound
inhibitori
activ
low
micromolar
level
merscov
replic
cell
cultur
vitro
identifi
fdaapprov
drug
librari
de
wild
et
al
mechan
action
well
defin
entri
inhibitor
class
antiretrovir
drug
prevent
viru
enter
cell
baldwin
et
al
liu
et
al
est
telenti
exemplifi
antihiv
peptid
enfuvirtid
entri
inhibitor
usual
good
compat
complementar
kind
drug
cocktail
therapi
increas
cur
effect
decreas
side
effect
lalezari
et
al
lazzarin
et
al
henc
viru
entri
inhibitor
could
serv
promis
candid
drug
merscov
infect
good
prospect
clinic
applic
review
summar
recent
advanc
studi
report
structur
function
merscov
spike
protein
lead
better
understand
merscov
entri
fusion
mechan
follow
address
develop
merscov
entryfus
inhibitor
target
subunit
merscov
spike
protein
particularli
focus
viral
fusion
inhibitor
interact
region
spike
protein
futur
applic
treatment
prevent
mer
similar
sarscov
merscov
spike
protein
also
type
transmembran
glycoprotein
locat
viral
envelop
surfac
trimer
state
merscov
protein
contain
amino
acid
cleav
two
subunit
fig
subunit
respons
bind
cellular
receptor
subunit
mediat
membran
fusion
lu
et
al
mou
et
al
lu
et
al
merscov
protein
locat
within
ntermin
amino
acid
protein
lu
et
al
chen
et
al
wang
et
al
contain
receptor
bind
domain
rbd
fig
although
crystal
structur
complex
previous
solv
use
multipl
sequenc
align
cartoon
merscov
fusion
core
structur
color
gray
color
green
respect
b
helic
wheel
residu
locat
posit
helic
wheel
hydrophob
conserv
b
c
f
posit
hydrophil
c
interact
interact
residu
locat
posit
yellow
three
residu
form
intern
trimer
residu
locat
e
g
posit
red
interact
residu
posit
blue
final
form
structur
sarscov
subunit
predict
rbd
merscov
might
locat
residu
later
three
independ
group
solv
crystal
structur
complex
determin
rbd
merscov
locat
residu
lu
et
al
chen
et
al
wang
et
al
also
show
core
structur
merscov
protein
rbd
fivestrand
antiparallel
sever
short
harbor
three
disulfid
bond
connect
order
stabil
core
structur
lu
et
al
rbd
also
contain
glycan
lu
et
al
chen
et
al
wang
et
al
receptor
bind
motif
rbd
domain
bind
sidesurfac
lu
et
al
interact
similar
interact
adenosin
deaminas
ada
weihofen
et
al
therefor
ada
compet
viru
bind
act
natur
antagonist
merscov
infect
raj
et
al
import
domain
mediat
bind
merscov
receptor
rbd
serv
critic
target
develop
vaccin
therapeut
hotez
et
al
other
previous
demonstr
merscov
rbd
could
induc
signific
neutral
antibodi
respons
mice
du
et
al
et
al
ying
et
al
provid
solid
rational
use
rbd
attract
target
develop
merscov
entri
inhibitor
solubl
rbdspecif
neutral
monoclon
antibodi
mab
multipl
sequenc
align
sarscov
protein
subunit
found
subunit
merscov
harbor
fusion
peptid
fp
residu
domain
residu
domain
residu
transmembran
domain
residu
intracellular
domain
fig
like
sarscov
subunit
merscov
subunit
respons
mediat
viral
fusion
target
cell
membran
merscov
bind
hypothes
subunit
chang
conform
insert
fp
target
cell
membran
helic
form
homotrim
exposur
three
highli
conserv
hydrophob
groov
surfac
molecul
bind
trimer
form
sixhelix
bundl
core
structur
bring
viral
cell
membran
close
proxim
facilit
fusion
fig
final
genet
materi
merscov
enter
host
cell
via
fusion
pore
replic
cytoplasm
altern
merscov
also
enter
cell
via
endocytosi
cathepsin
land
low
phdepend
manner
qian
et
al
shirato
et
al
analysi
found
merscov
use
fusogen
mechan
enter
target
cell
similar
hiv
sarscov
enter
target
cell
chan
kim
liu
et
al
liu
et
al
liu
et
al
yu
et
al
residu
posit
one
helic
interact
residu
posit
adjac
helic
respect
form
intern
trimer
locat
e
g
posit
helic
interact
residu
e
g
posit
helic
form
fig
residu
b
c
f
posit
helic
form
hydrophil
face
toward
solut
maintain
watersolubl
oligomer
bundl
fig
crystal
structur
merscov
notabl
differ
length
observ
helic
fig
nand
ctermin
tail
region
pack
orderli
manner
hydrophob
groov
trimer
sever
hydrophob
interact
mainli
distribut
ntermin
portion
ctermin
portion
one
helix
form
hydrogen
bond
interact
two
neighbor
domain
hydrogen
bond
locat
ntermin
ctermin
portion
helix
constitut
two
anchor
point
ncap
ccap
conform
stabil
construct
compar
fusion
core
structur
sarscov
protein
xu
et
al
merscov
subunit
contain
stronger
hydrogen
bond
suggest
merscov
protein
stabl
sarscov
protein
reason
peptid
deriv
merscov
expect
effect
merscov
fusion
peptid
deriv
sarscov
sarscov
fusion
find
confirm
region
merscov
protein
subunit
promis
target
peptidesbas
merscov
fusion
inhibitor
merscov
infect
initi
bind
viral
particl
via
rbd
protein
viral
surfac
cellular
receptor
cell
surfac
target
bind
site
rbd
receptor
could
block
initi
step
viru
entri
thu
might
provid
superior
pharmacolog
action
suppress
merscov
infect
regard
could
serv
excel
blocker
attach
entri
merscov
cell
inde
found
bind
merscov
rbd
high
affin
ying
et
al
prevent
infect
pseudotyp
merscov
ic
gml
tabl
addit
protein
fragment
chemic
modif
may
improv
antivir
activ
pharmacolog
properti
altern
antibodi
could
also
block
interact
cellular
viral
rbd
thu
inhibit
merscov
infect
ohnuma
et
al
howev
impract
appli
approach
vivo
play
import
role
sever
distinct
signal
pathway
regul
mani
peptid
zhong
et
al
bind
antibodi
cell
surfac
may
pleiotrop
effect
host
furthermor
gml
present
serum
ohnuma
et
al
signific
amount
antibodi
neutral
antibodi
bind
cellular
inhibit
viru
bind
infect
howev
intranas
applic
antibodi
prevent
merscov
expect
circumv
problem
mention
previous
found
merscov
rbd
could
induc
signific
neutral
antibodi
respons
mice
find
result
develop
neutral
mous
monoclon
antibodi
mab
potent
block
merscov
entri
human
cell
neutral
mab
gener
immun
mice
recombin
merscov
fuse
ctermin
fc
tag
stabl
hybridoma
cell
line
gener
screen
posit
clone
subsequ
select
antimerscov
mab
test
inhibit
pseudoviru
entri
mediat
merscov
spike
protein
neutral
activ
live
merscov
infect
vero
cell
mab
potent
antimerscov
activ
select
highli
effect
block
entri
merscov
spikemedi
pseudovirus
cell
also
potent
neutral
live
merscov
infect
permiss
vero
cell
inhibit
format
merscovinduc
cpe
addit
effici
attenu
format
merscovinduc
cpe
permiss
cell
confirm
potent
antimerscov
neutral
activ
tabl
investig
mechan
neutral
merscov
cell
entri
rbdreceptorbind
assay
perform
presenc
found
bind
merscov
rbd
cell
block
dosedepend
manner
suggest
neutral
merscov
entri
host
cell
block
bind
merscov
rbd
host
receptor
also
found
specif
bound
merscov
rbdfc
merscov
human
fc
hfc
furthermor
lost
bind
affin
merscov
rbd
presenc
dtt
result
suggest
specif
bind
merscov
rbd
recogn
conform
epitop
rbd
thu
human
serv
potent
passiv
immunotherapeut
agent
prevent
treat
merscov
infect
recent
neutral
human
mab
merscov
also
report
ying
et
al
construct
larg
phagedisplay
antibodi
fab
librari
use
b
cell
blood
healthi
donor
ying
et
al
screen
librari
recombin
merscov
rbd
panel
human
mab
identifi
three
mab
bound
rbd
picomolar
affin
select
character
remark
three
rbdspecif
mab
exhibit
except
potent
neutral
activ
mab
neutral
pseudotyp
merscov
inhibitori
concentr
ic
rang
gml
tabl
particularli
noteworthi
potent
mab
inhibit
merscov
pseudoviru
infect
ic
concentr
gml
similarli
show
potent
live
viru
neutral
activ
ic
gml
tabl
three
mab
compet
bind
merscov
rbd
potent
inhibit
bind
rbd
receptor
consist
neutral
result
slightli
potent
either
block
bind
rbd
receptor
ic
gml
respect
result
suggest
mab
neutral
merscov
compet
host
receptor
bind
viru
overlap
epitop
local
mab
epitop
panel
rbd
alaninescan
mutant
develop
key
residu
rbd
involv
bind
mab
identifi
interestingli
three
rbdspecif
mab
possess
overlap
distinct
epitop
suggest
possibl
synergist
effect
use
three
mab
combin
molecular
model
dock
rbdspecif
mab
merscov
rbd
confirm
epitop
identifi
rbd
alaninescan
mutant
also
indic
possibl
domin
role
heavi
chain
mab
paratop
extens
overlap
mab
epitop
receptor
bind
site
rbd
explain
except
neutral
potenc
mab
two
group
also
identifi
sever
potent
human
mab
jiang
et
al
use
nonimmun
yeastdisplay
scfv
librari
screen
recombin
merscov
rbd
identifi
two
potent
rbdspecif
neutral
mab
potent
mab
neutral
pseudotyp
merscov
ic
gml
neutral
live
merscov
ic
gml
tabl
mab
could
inhibit
bind
solubl
rbd
suscept
cell
suggest
neutral
mechan
also
occur
block
rbd
bind
cellular
receptor
epitop
map
mutagenesi
key
residu
rbd
also
perform
found
recogn
differ
epitop
rbd
inde
combin
demonstr
synergist
neutral
effect
pseudotyp
merscov
meanwhil
tang
et
al
also
identifi
neutral
mab
nonimmun
phagedisplay
scfv
librari
pan
perform
sequenti
use
merscov
spikecontain
paramagnet
proteoliposom
cell
express
fulllength
protein
antigen
panel
scfv
identifi
express
scfvfc
format
epitop
map
use
differ
fragment
suggest
epitop
seven
mab
also
lie
within
rbd
domain
bind
competit
assay
indic
seven
mab
could
recogn
least
three
differ
epitop
merscov
rbd
potent
antibodi
neutral
merscov
viru
ic
gml
scfvfc
format
gml
igg
format
tabl
antibodi
could
block
bind
merscov
rbd
inhibit
attach
pseudoviru
cell
could
also
block
antibodi
rbd
bind
result
confirm
neutral
mechan
also
occur
block
merscov
rbd
bind
cellular
receptor
monoclon
antibodi
enjoy
signific
clinic
success
use
effect
treatment
number
diseas
particular
cancer
immun
disord
although
mab
approv
clinic
use
human
mab
palivizumab
synagi
scott
lamb
remain
mab
approv
fda
use
viral
diseas
howev
increas
number
mab
emerg
virus
includ
sarscov
henipavirus
well
virus
develop
mani
exhibit
high
potenc
vitro
anim
model
infect
casadeval
et
al
prabakaran
et
al
interestingli
identifi
highli
potent
merscov
mab
target
rbd
domain
merscov
glycoprotein
like
util
competit
mechan
viru
neutral
confirm
rbd
critic
target
develop
merscov
vaccin
therapeut
high
neutral
activ
newli
identifi
mab
especi
suggest
show
except
promis
prophylaxi
therapi
merscov
infect
human
tang
et
al
ying
et
al
two
decad
ago
other
identifi
sever
highli
potent
fusion
inhibitor
deriv
region
jiang
et
al
wild
et
al
one
peptid
approv
us
fda
first
hiv
fusionentri
inhibitor
treatment
patient
fail
respond
current
antiretrovir
drug
kilbi
eron
lalezari
et
al
lazzarin
et
al
sinc
seri
increas
antihiv
activ
improv
pharmacolog
properti
resist
profil
sft
chong
et
al
pan
et
al
et
al
identifi
mechan
action
peptid
well
document
bind
coreceptor
trigger
seri
conform
chang
includ
insert
fusion
peptid
fp
target
cell
membran
exposur
prehairpin
coil
coil
domain
associ
viral
domain
trimer
result
format
sixhel
bundl
final
bring
viral
envelop
cell
membran
close
proxim
fusion
prefus
intermedi
state
synthet
peptid
ad
also
bind
viral
form
heterolog
block
viruscel
fusion
liu
et
al
discoveri
hiv
fusion
inhibitor
open
new
avenu
identifi
develop
peptid
viral
entri
inhibitor
envelop
virus
class
membran
fusion
protein
ebola
viru
nipahviru
hendraviru
paramyxovirus
newcastl
diseas
viru
simian
immunodefici
viru
siv
felin
immunodefici
viru
fiv
respiratori
syncyti
viru
rsv
blacklow
et
al
lombardi
et
al
watanab
et
al
yu
et
al
wang
et
al
ten
year
ago
design
peptid
deriv
sarscov
protein
subunit
domain
name
found
could
interact
peptid
deriv
domain
sarscov
protein
subunit
form
stabl
inhibit
sarscov
infect
vero
cell
ic
later
sever
group
also
identifi
sarscov
fusion
inhibitori
peptid
region
antisarscov
activ
similar
bosch
et
al
yuan
et
al
zheng
et
al
sequenc
align
analysi
sarscov
merscov
protein
subunit
predict
domain
merscov
protein
locat
region
overlap
residu
respect
crystal
structur
canon
form
domain
solv
notic
helic
region
residu
domain
close
interact
helic
region
residu
domain
fig
base
structur
inform
design
synthes
two
peptid
residu
contain
residu
residu
contain
residu
fig
determin
abil
design
peptid
form
first
develop
fluoresc
nativ
polyacrylamid
gel
electrophoresi
fnpage
base
fnpage
use
test
format
peptid
chan
kim
liu
et
al
liu
et
al
liu
et
al
label
fitc
xcell
surelock
minicel
invitrogen
carlsbad
ca
use
npage
low
molecular
weight
lmw
marker
obtain
amersham
pharmacia
biotech
inc
piscataway
nj
peptid
pb
control
pb
incub
pb
control
pb
c
min
sampl
mix
trisglycin
nativ
sampl
buffer
invitrogen
carlsbad
ca
ratio
load
precast
gel
well
mm
thick
l
well
gel
electrophoresi
carri
v
constant
voltag
room
temperatur
h
immedi
electrophoresi
fluoresc
band
gel
imag
fluorchem
imag
system
use
transillumin
uv
light
sourc
excit
wavelength
nm
fluoresc
filter
emiss
wavelength
nm
fig
upper
panel
gel
stain
coomassi
blue
explor
distribut
peptid
fig
lower
panel
similar
npage
protein
peptid
kept
natur
state
condit
fnpage
migrat
speed
direct
depend
either
molecular
weight
net
charg
nativ
electrophoresi
condit
show
band
carri
net
posit
charg
thu
migrat
gel
show
one
band
lower
posit
combin
show
two
band
lower
one
posit
new
upper
band
increas
concentr
intens
upper
band
increas
intens
lower
band
decreas
suggest
upper
band
complex
form
lower
band
isol
use
sizeexclus
hplc
assess
interact
merscov
previous
describ
analyz
format
peptid
chan
kim
liu
et
al
liu
et
al
liu
et
al
yu
et
al
alon
exhibit
singl
peak
ml
combin
show
new
peak
ml
fig
result
confirm
could
interact
form
oligomer
complex
subsequ
analyz
complex
use
sd
polyacrylamid
protein
gel
without
heat
sampl
alon
show
band
molecular
weight
kda
complex
exhibit
band
kda
correspond
predict
mass
form
kda
final
use
circulardichro
cd
spectroscopi
determin
secondari
structur
assess
thermal
stabil
complex
mixtur
equimolar
concentr
show
typic
helic
complex
thermal
stabil
complex
merscov
protein
phosphat
buffer
tm
c
much
higher
complex
form
peptid
deriv
sarscov
protein
subunit
respect
chan
kim
liu
et
al
liu
et
al
liu
et
al
combin
result
differ
biophys
biochem
experi
conclud
peptid
deriv
domain
merscov
protein
subunit
could
interact
form
highli
stabl
mimick
viral
fusion
core
structur
form
entir
domain
merscov
protein
shown
crystallograph
analysi
develop
merscov
proteinmedi
cellcel
fusion
model
test
membran
fusion
inhibitori
activ
peptid
use
cell
express
membran
surfac
target
cell
cell
instantan
coexpress
merscov
protein
egfp
effector
cell
cell
cocultur
cell
c
h
use
cell
express
egfp
control
cell
fusion
cell
visibl
fluoresc
microscopi
shown
fig
fuse
cell
show
larger
size
weaker
fluoresc
unfus
cell
fluoresc
one
cell
diffus
two
cell
fuse
togeth
stain
cell
nucleu
dapi
could
clearli
visual
presenc
two
nuclei
one
fuse
cell
larger
size
weaker
fluoresc
unfus
cell
one
nucleu
find
confirm
merscov
protein
abl
mediat
membran
fusion
effector
target
cell
use
merscov
proteinmedi
cellcel
fusion
model
test
inhibitori
activ
deriv
domain
respect
merscov
protein
subunit
result
indic
exhibit
potent
inhibitori
effect
ic
exhibit
appreci
activ
peptid
deriv
sarscov
protein
exhibit
inhibitori
activ
merscov
smediat
cellcel
fusion
suggest
peptid
deriv
differ
envelop
virus
crossinhibit
viral
fusion
even
though
peptid
similar
mechan
action
also
show
potent
inhibitori
activ
pseudotyp
live
merscov
infect
cell
vero
cell
tabl
improv
stabil
solubl
antivir
activ
adapt
approach
describ
otaka
et
al
modifi
peptid
introduc
ek
mutat
form
new
intramolecular
saltbridg
otaka
et
al
design
synthes
two
mutant
point
mutat
point
mutat
order
increas
saltbridg
hydrophil
found
exhibit
increas
peptid
solubl
water
around
pb
respect
inhibitori
activ
merscov
smediat
cellcel
fusion
also
increas
result
suggest
antivir
activ
pharmacolog
properti
peptid
improv
use
differ
approach
optim
like
envelop
virus
class
membran
fusion
protein
eg
hiv
sarscov
merscov
also
util
spike
protein
enter
target
cell
rbd
protein
subunit
respons
viru
bind
receptor
target
cell
domain
protein
subunit
respons
mediat
fusion
viral
envelop
target
cell
membran
entri
may
serv
target
develop
merscov
entryfus
inhibitor
rbdspecif
neutral
mab
fusion
inhibitori
peptid
base
previou
experi
develop
peptid
fusion
inhibitor
hiv
jiang
et
al
wild
et
al
sarscov
success
identifi
sever
specif
merscov
peptid
fusion
inhibitor
like
hiv
fusion
inhibitor
enfuvirutid
peptid
deriv
domain
subunit
merscov
spike
protein
specif
bind
domain
subunit
viral
merscov
spike
protein
form
stabl
block
viral
fusion
core
format
result
inhibit
fusion
viral
envelop
target
cell
membran
peptid
show
except
promis
develop
effect
safe
therapeut
prophylact
agent
treatment
prevent
mer
clinic
applic
hiv
fusion
inhibitor
sever
limit
longterm
repeat
use
includ
seriou
local
inject
reaction
induct
antipeptid
drug
antibodi
drugresist
viru
mutant
peptid
drug
virus
caus
acut
often
fatal
infecti
diseas
merscov
gener
administ
inject
short
period
time
make
limit
moot
furthermor
merscov
fusion
inhibitori
peptid
may
also
intranas
use
avoid
local
inject
reaction
previou
studi
shown
addit
fatti
acid
cholesterol
antihiv
peptid
drug
result
signific
increas
antivir
activ
wexlercohen
shai
ingallinella
et
al
lee
et
al
ashkenazi
et
al
conjug
peg
peptid
drug
expect
follow
advantag
prolong
halflif
vivo
decreas
degrad
metabol
enzym
reduct
elimin
protein
immunogen
verones
verones
pasut
pasut
verones
therefor
strategi
also
appli
modifi
merscov
fusion
inhibitori
peptid
improv
antivir
potenc
pharmacolog
properti
rbd
subunit
domain
subunit
also
use
target
screen
smallmolecul
merscov
entri
inhibitor
small
molecul
bind
merscov
rbd
domain
reason
affin
specif
consid
altern
mab
inhibitori
peptid
use
small
molecul
could
advantag
certain
circumst
easier
less
expens
product
compar
biolog
molecul
moreov
highresolut
structur
complex
well
sixhelix
bundl
fusion
core
merscov
spike
protein
subunit
offer
signific
opportun
structurebas
ration
design
entri
inhibitor
target
rbd
domain
merscov
spike
protein
long
vivo
halflif
superior
stabil
mab
develop
immunotherapeut
treat
prevent
merscov
infect
although
rbdspecif
neutral
mab
fusion
inhibitori
peptid
display
high
potenc
inhibit
viral
entri
merscov
target
differ
step
viral
entri
viral
attach
receptor
cell
surfac
viral
fusion
target
cell
membran
respect
therefor
reason
specul
combin
neutral
mab
peptid
may
synergist
effect
merscov
infect
well
known
combinatori
use
hiv
revers
transcriptas
rt
inhibitor
proteas
inhibitor
known
highli
activ
antiretroviru
therapi
haart
perelson
et
al
louie
et
al
di
et
al
shown
signific
synerg
inhibit
infect
reduc
advers
effect
delay
emerg
drug
resist
hogg
et
al
thu
extend
lifespan
million
hivaid
patient
simon
et
al
richman
et
al
one
may
question
whether
use
peptid
rbdspecif
neutral
antibodi
control
merscov
infect
may
drive
viru
evolut
result
emerg
viral
mutant
resist
fusion
inhibitor
neutral
antibodi
unlik
longterm
treatment
hiv
infect
chronic
infecti
diseas
shortterm
treatment
mer
sar
acut
infecti
diseas
may
provid
less
opportun
time
allow
viru
make
drugresist
mutat
far
one
natur
mutat
posit
domain
merscov
spike
protein
found
cotten
et
al
howev
report
shown
mutat
affect
sensit
mutant
viru
merscov
fusion
inhibitor
rbd
merscov
spike
protein
rel
conserv
ying
et
al
cotten
et
al
combin
use
peptid
rbdspecif
neutral
antibodi
conjug
consist
peptid
rbdbind
molecul
like
bifunct
antihiv
protein
xu
et
al
expect
effect
merscov
mutat
spike
protein
domain
rbd
diminish
chanc
induc
drugresist
viral
mutant
consid
merscov
entri
target
cell
may
occur
dual
pathway
ie
plasma
membran
fusion
endocytosi
may
necessari
use
membran
fusion
inhibitor
endocytosi
inhibitor
combin
clinic
use
drug
chlorpromazin
report
function
endocytosi
inhibitor
sarscov
inou
et
al
merscov
de
wild
et
al
falzarano
et
al
demonstr
efficaci
combin
ribavirin
reduc
merscov
replic
vitro
combin
given
rhesu
macaqu
within
hour
inocul
merscov
treatment
result
benefici
effect
reduc
viru
replic
lung
injuri
inflamm
improv
clinic
outcom
therefor
approach
limit
combin
merscov
entri
inhibitor
target
differ
site
spike
protein
rather
includ
combin
merscov
entri
inhibitor
specif
antimerscov
agent
target
step
merscov
replic
proteas
inhibitor
furthermor
combin
specif
antimerscov
agent
nonspecif
merscov
replic
inhibitor
identifi
fdaapprov
drug
librari
de
wild
et
al
may
also
synergist
effect
overal
anticip
endeavor
lead
highli
effect
therapeut
approach
treatment
mer
patient
prevent
merscov
infect
highrisk
popul
includ
healthcar
worker
famili
member
